 Mesoblast Limited NASDAQ: MESO received feedback from the FDAs Office of Tissues and Advanced Therapies OTAT on the Phase 3 program of rexlemestrocel-L in patients. The trial is assessing rexlemestrocel-L in patients with chronic low back pain CLBP due to degenerative disc disease refractory to available therapies, including opioids. 